Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content Skip to footer

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Shots:

  • The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industry
  • In February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative Colitis
  • PharmaShots has compiled a list of a total of 8 new drugs approved by the EMA in February 2024

1. Pfizer’s Velsipity (etrasimod) Receives the European Commission’s Approval for the Treatment of Severely Active Ulcerative Colitis

Product Name: Velsipity

Active ingredient: Etrasimod

Company: Pfizer

Date: Feb 20, 2024

Disease: Ulcerative Colitis

Shots:

  • The positive opinion was granted by CHMP based on the results from the P-III (CARTITUDE-4) clinical trial evaluating the safety & efficacy of Carvykti vs Standard Therapy (Pomalidomide, Bortezomib & Dexamethasone (PVd)/Daratumumab, Pomalidomide and Dexamethasone (DPd)) in patients with r/lenalidomide-r multiple myeloma
  • Patients in the trial have previously received 1-3 prior lines of therapy, depicted disease progression on the last therapy & were refractory to lenalidomide
  • Carvykti is a BCMA-directed genetically modified autologous T-cell immunotherapy that has received a CMA from the EMA in May 2022 & approval from the US FDA in Feb 2022 for the treatment of r/r MM

2. Biogen’s Qalsody (tofersen) Receives CHMP’s Positive Opinion for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Product Name: Qalsody

Active ingredient: Tofersen

Company: Biogen

Date: Feb 23, 2024

Disease: Amyotrophic Lateral Sclerosis (ALS)

Shots:

  • The opinion was based on the results from the P-III (VALOR) trial evaluating the safety & efficacy of Qalsody (100mg) vs PBO in ALS patients (n=108) associated with SOD1 mutations. The 1EPs of the study include changes in ALSFRS-R total score from baseline to wk.28 & 2EPs includes change in total cerebrospinal fluid SOD1 protein concentration, plasma NfL, slow vital capacity & handheld dynamometry in 16 muscles
  • The results depicted a 60% reduction in plasma NfL & an improvement in physical abilities measured by ALSFRS-R total score with Qalsody vs PBO
  • Qalsody, an antisense oligonucleotide (ASO), binds to SOD1 mRNA to reduce SOD1 protein production. Additionally, Qalsody received the US FDA’s accelerated approval for ALS

3. Janssen’s Type II Variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) Receives CHMP’s Positive Opinion to Treat Multiple Myeloma

Product Name: Carvykti

Active ingredient: Ciltacabtagene autoleucel; Cilta-cel

Company: Janssen Pharmaceuticals

Date: Feb 23, 2024

Disease: Multiple Myeloma (MM)

Shots:

  • The positive opinion was granted by CHMP based on the results from the P-III (CARTITUDE-4) clinical trial evaluating the safety & efficacy of Carvykti vs Standard Therapy (Pomalidomide, Bortezomib & Dexamethasone (PVd)/Daratumumab, Pomalidomide and Dexamethasone (DPd)) in patients with r/lenalidomide-r multiple myeloma
  • Patients in the trial have previously received 1-3 prior lines of therapy, depicted disease progression on the last therapy & were refractory to lenalidomide
  • Carvykti is a BCMA-directed genetically modified autologous T-cell immunotherapy that has received a CMA from the EMA in May 2022 & approval from the US FDA in Feb 2022 for the treatment of r/r MM

4. Merck’s Keytruda (pembrolizumab) in Combination with Chemotherapy Receives CHMP’s Positive Opinion for the Treatment of Non-Small Cell Lung Cancer

Product Name: Keytruda

Active ingredient: Pembrolizumab

Company: Merck

Date: Feb 23, 2024

Disease: Non-Small Cell Lung Cancer (NSCLC)

Shots:

  • The company received the positive opinion based on the results from the P-III (KEYNOTE-671) clinical trial evaluating neoadjuvant Keytruda + platinum-containing CT followed by adjuvant Keytruda monotx. vs neoadjuvant PBO in patients with resectable NSCLC at high risk of recurrence
  • The study met its dual 1EP by demonstrating a statistically significant & clinically meaningful improvement in OS and EFS. Additionally, based on these results the company expects to receive EC’s decision by H1’24
  • Earlier in Oct 2023, Keytruda in combination with platinum-containing CT received the US FDA’s approval for the treatment of patients with resectable (tumors ≥4 cm or node-positive) NSCLC

4. Vertex Receives CHMP’s Positive Opinion for Kalydeco as a Treatment of Cystic Fibrosis in Infants

Product Name: Kalydeco

Active ingredient: Ivacaftor

Company: Vertex Pharmaceuticals

Date: Feb 23, 2024

Disease: Cystic Fibrosis

Shots:

  • The company received the CHMP’s positive opinion for the label expansion of Kalydeco (Ivacaftor) to include the treatment of infants (aged 1mos.-4mos.) with cystic fibrosis with specific mutations in the CFTR gene (R117H/G551D/G1244E/G1349D/G178R/G551S/S1251N/S1255P/S549N/S549R)
  • Kalydeco has been approved by the EU for the treatment of cystic fibrosis patients aged ≥4mos. with specific CFTR gene mutations
  • Kalydeco is an oral medicine designed to enhance the ability of the CFTR protein to transport salt and water across the cell membrane thereby hydrating and clearing mucus from the airways

5. BMS’ Reblozyl Gains CHMP’s Positive Opinion to Treat Transfusion-Dependent Anemia Due to Myelodysplastic Syndrome (MDS)

Product Name: Reblozyl 

Active ingredient: Luspatercept 

Company: Bristol Myers Squibb

Date: Feb 26, 2024

Disease: Transfusion-Dependent Anemia Due to Myelodysplastic Syndrome (MDS)

Shots:

  • The positive opinion was supported by the P-III (COMMANDS) study assessing the safety & efficacy of Reblozyl (1.0mg/kg, titration ~1.75mg/kg, Q3W) vs epoetin alfa (450 IU/kg, titration ~1050IU/kg, QW) for ≥24 wks. to treat transfusion-dependent anemia due to very low-, low- or intermediate-risk (IPSS-R) MDS in patients naïve to erythropoiesis-stimulating agent
  • The data, as of Mar 2023, in patients (n=363) depicted RBC-TI of at least 12wks. in 60.4% vs 34.8% with mean Hb increase of ~1.5 g/dL in first 24wks., 74.2% vs 53% had HI-E increase of at least 8wks., 68.1% vs 48.6% experienced RBC-TI of at least 12wks.& a DoR of 128.1wks. vs 89.7wks.
  • The safety profile was consistent with the prior MDS programs


6. AstraZeneca’s Voydeya Receives CHMP’s Recommendation for Treating Paroxysmal Nocturnal Haemoglobinuria (PNH) with Residual Haemolytic Anaemia

Product Name: Voydeya

Active ingredient: Danicopan

   Company: AstraZeneca

   Date: Feb 26, 2024

   Disease: Paroxysmal Nocturnal Haemoglobinuria (PNH) with Residual Haemolytic Anaemia

   Shots:

  • The CHMP has recommended Voydeya as an add-on therapy to SoC for treating PNH adult patients with residual haemolytic anaemia
  • The recommendation was based on the P-III (ALPHA) study investigating the safety & efficacy of Voydeya as an add-on therapy to Ultomiris or Soliris (SoC) for treating PNH patients with extravascular haemolysis (EVH)
  • The study achieved its 1EP of change in hemoglobin from baseline to wk. 12 along with the 2EPs incl. transfusion avoidance and change in Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue) score. The drug was well tolerated without any safety concerns. Data from the 12-wk. primary analysis was published in The Lancet Haematology

7. CSL Vifor and Travere Therapeutics’ Filspari (sparsentan) Gains CHMP’s Positive Opinion to Treat IgA Nephropathy

Product Name: Filspari

Active ingredient: Sparsentan

Company: CSL Vifor and Travere Therapeutics

Date: Feb 26, 2024

Disease: IgA Nephropathy

Shots:

  • The CHMP has granted positive opinion to CSL (exclusive commercialization rights holder in the EU, Australia & New Zealand) & Travere’s sparsentan for its conditional approval to treat primary IgAN with a urine protein excretion >1.0 g/day. EC’s decision is anticipated in Q2’24
  • The opinion was supported by the P-III (PROTECT) trial investigating the safety & efficacy of sparsentan (400mg) vs irbesartan (300mg) in IgAN patients (n=404, 18yrs. of age & above) with persistent proteinuria after receiving MTD and at least -50% of maximum labelled dose of ACE/ARB therapy
  • The results depicted fast & sustained proteinuria reduction, ability of sparsentan to preserve kidney function & delay time to kidney failure

8. BeiGene’s Tevimbra (tislelizumab) Receives CHMP’s Positive Opinion for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

   Product Name: Tevimbra

   Active ingredient: Tislelizumab

  Company: BeiGene

  Date: Feb 27, 2024

  Disease: Non-Small Cell Lung Cancer (NSCLC)

  Shots:

  • The MAA was based on the evaluation of NSCLC patients (n=1,499) in 3 P-III studies incl. (RATIONALE 307) for Tevimbra + carboplatin + paclitaxel/nab-paclitaxel vs CT (1L treatment for sq. NSCLC), (RATIONALE 304) for Tevimbra + pemetrexed + platinum-containing CT vs CT (1L treatment for non-sq. NSCLC) & (RATIONALE 303) for Tevimbra vs CT (locally advanced/metastatic NSCLC)
  • At 8.6mos. follow-up, (RATIONALE 307) showed a PFS of 7.6 & 7.6 vs 5.5mos. & ORR of 72.5 & 74.8 vs 49.6%, at 9.8mos. follow-up (RATIONALE 304) showed a PFS of 9.7 vs 7.6mos & (RATIONALE 303) showed an OS of 17.2 vs 11.9mos.
  • Tevimbra, an IgG4 anti-PD-1 mAb, received the EC’s approval for ESCC in 2023 & is under review by the US FDA for ESCC

Note:

According to the EMA’s February 2024 approval list, Seqirus Netherlands B.V.’s Incellipan and Celldemic, Incyte Biosciences’ Zynyz, Pfizer’s Cibinqo, Nova Laboratories’ Xromi was also approved; however, no PR was available

Related Post: Insights+: EMA Marketing Authorization of New Drugs in January 2024

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]